Hepatocyte-specific, PPAR γ -regulated mechanisms to promote steatosis in adult mice

Abigail Wolf Greenstein^{1,2,3,*}, Neena Majumdar^{1,2,*}, Peng Yang^{1,2},
Papasan V Subbaiah^{1,2}, Rhonda D Kineman^{1,2} and Jose Cordoba-Chacon^{1,2}

¹Research and Development Division, Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA

²Section of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, USA

³Biologic Resources Laboratory, University of Illinois at Chicago, Chicago, Illinois, USA

*(A Wolf Greenstein and N Majumdar contributed equally to this work)

Correspondence
should be addressed
to J Cordoba-Chacon
Email
jcordoba@uic.edu

Abstract

Peroxisome proliferator-activated receptor γ (PPAR γ) is the target for thiazolidinones (TZDs), drugs that improve insulin sensitivity and fatty liver in humans and rodent models, related to a reduction in hepatic *de novo* lipogenesis (DNL). The systemic effects of TZDs are in contrast to reports suggesting hepatocyte-specific activation of PPAR γ promotes DNL, triacylglycerol (TAG) uptake and fatty acid (FA) esterification. As these hepatocyte-specific effects of PPAR γ could counterbalance the positive therapeutic actions of systemic delivery of TZDs, the current study used a mouse model of adult-onset, liver (hepatocyte)-specific PPAR γ knockdown (aLivPPAR γ kd). This model has advantages over existing congenital knockout models, by avoiding compensatory changes related to embryonic knockdown, thus better modeling the impact of altering PPAR γ on adult physiology, where metabolic diseases most frequently develop. The impact of aLivPPAR γ kd on hepatic gene expression and endpoints in lipid metabolism was examined after 1 or 18 weeks (Chow-fed) or after 14 weeks of low- or high-fat (HF) diet. aLivPPAR γ kd reduced hepatic TAG content but did not impact endpoints in DNL or TAG uptake. However, aLivPPAR γ kd reduced the expression of the FA translocase (Cd36), in 18-week Chow- and HF-fed mice, associated with increased NEFA after HF feeding. Also, aLivPPAR γ kd dramatically reduced Mogat1 expression, that was reflected by an increase in hepatic monoacylglycerol (MAG) levels, indicative of reduced MOGAT activity. These results, coupled with previous reports, suggest that Cd36-mediated FA uptake and MAG pathway-mediated FA esterification are major targets of hepatocyte PPAR γ , where loss of this control explains in part the protection against steatosis observed after aLivPPAR γ kd.

Key Words

- ▶ adult-onset hepatocyte-specific knockdown
- ▶ Cd36
- ▶ Mogat1
- ▶ LC/MS
- ▶ diet-induced steatosis

Journal of Endocrinology
(2017) **232**, 107–121

Introduction

Non-alcoholic fatty liver disease (NAFLD) is defined as excessive accumulation of fat (steatosis) within hepatocytes that is independent of alcohol intake. NAFLD increases

the risk of diabetes, non-alcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma (Michelotti *et al.* 2013, Lade *et al.* 2014). Importantly, NAFLD is now

recognized as the leading cause of chronic liver disease in the US (Younossi *et al.* 2011) and the third most common reason for liver transplants (Zezos & Renner 2014). Given the negative association between NAFLD and human health, a concerted effort is being made to understand the cellular and molecular mechanisms that control hepatocyte triacylglycerol (TAG) content. It is clear that hepatocyte TAG content is dictated by the balance between fatty acid (FA) synthesis, uptake, esterification and oxidation, as well as TAG release via very-low-density lipoprotein (VLDL) (Browning & Horton 2004). A better understanding of the mechanisms controlling these processes could help to identify individuals with higher risk of NAFLD, as well as identify novel drug targets to design therapeutic strategies that prevent or reverse NAFLD progression.

Thiazolidinones (TZDs) are synthetic agonists of the nuclear receptor, peroxisome proliferator-activated receptor γ (PPAR γ) used to treat diabetes type 2 (Ahmadian *et al.* 2013). Treating patients with non-alcoholic steatohepatitis (an advance stage of NAFLD featured by elevated markers of liver injury and fibrosis) with TZDs reduces steatosis with variable effects on fibrosis (Belfort *et al.* 2006, Ratziu *et al.* 2008, Sanyal *et al.* 2010). The reduction in steatosis is associated with a reduction in hepatic *de novo* lipogenesis (DNL; Beysen *et al.* 2008). Similar to clinical studies, TZDs have also been shown to reduce hepatic fat content in rodent models (Nan *et al.* 2009, Gupte *et al.* 2010). However, in striking contrast to the global impact of TZDs: (1) hepatocyte-specific PPAR γ expression is positively associated with fatty liver in humans (Pettinelli & Videla 2011) and mouse models (Rahimian *et al.* 2001, Gavrilova *et al.* 2003, Matsusue *et al.* 2003, Inoue *et al.* 2005); (2) adenoviral overexpression of a PPAR γ transgene in the liver of high-fat (HF)-fed PPAR α knockout or WT mice dramatically increases hepatic fat content (Yu *et al.* 2003, Bai *et al.* 2011); (3) congenital hepatocyte-specific knockout of PPAR γ reduces hepatic fat content in mice fed a HF diet (Moran-Salvador *et al.* 2011), as well as in mice with fatty liver due to inactivating mutations in the leptin gene (*ob/ob*; Matsusue *et al.* 2003) or lipodystrophy induced by lack of adipocyte development (AZIP; Gavrilova *et al.* 2003). This disconnect between the impact of systemic TZD (PPAR γ agonist) delivery compared to the impact of hepatocyte-specific alterations in PPAR γ function can be attributed to the integrated effects of PPAR γ on multiple target tissues. Specifically, TZDs increase systemic insulin sensitivity, which in turn reduces insulin demands. These changes are associated with an increase in adiponectin production by

the adipocyte. Adiponectin in turn promotes hepatic fatty acid oxidation via phosphorylation of AMPK and ACC (Yamauchi *et al.* 2002, Xu *et al.* 2003), which suppresses DNL (Xu *et al.* 2003). Therefore, TZD's effects on lowering steatosis are likely due to extra-hepatocyte mechanisms (Furnsinn & Waldhaussl 2002).

Although the global therapeutic effects of TZDs have been largely positive, the direct actions of PPAR γ on the hepatocyte could serve to counterbalance these effects. Therefore, to optimize the development and use of TZDs, it is important to understand the tissue (cell)-specific impact of PPAR γ on lipid homeostasis. With respect to the hepatocyte, studies using hepatocyte-specific PPAR γ -knockout models have led to the conclusion that PPAR γ directly promotes hepatic fat accumulation by increasing lipid uptake, as well as promoting DNL (Gavrilova *et al.* 2003, Matsusue *et al.* 2003, 2014, Schadinger *et al.* 2005, Zhang *et al.* 2006). However, it remains unclear if the shifts in hepatic gene expression that support these conclusions are due directly to loss of hepatocyte PPAR γ or to compensation by other hepatic genes during development and/or secondary to changes in the systemic metabolic milieu. Therefore, in the current study, we have employed a mouse model of adult-onset, hepatocyte-specific knockdown of PPAR γ (aLivPPAR γ kd), that is generated by treating adult (10 weeks) PPAR $\gamma^{\Delta/\Delta}$ mice with an adeno-associated virus serotype 8 (AAV8) bearing a liver-specific thyroxine-binding globulin (TBG)-promoter driving a Cre recombinase transgene (AAV8-TBGp-Cre) vector. This model allows us to study the immediate impact of hepatocyte-specific loss of PPAR γ in the adult liver and how this deficit influences liver function overtime under different dietary conditions. As indicated in this study and supported by accumulating evidence (Yanger *et al.* 2014, Ashpole *et al.* 2016, Shin *et al.* 2016), injection of AAV8-TBGp-Cre is an efficient and reproducible method to knockdown a floxed allele only in hepatocytes, independent of age.

Analysis of changes in hepatic gene expression and circulating metabolites, combined with assessment of hepatic FA composition (gas chromatography/mass spectrometry (GC/MS)) and relative levels of TAG, diacylglycerols (DAG) and monoacylglycerols (MAG) (liquid chromatography/mass spectrometry (LC/MS)), indicate that adult-onset loss of hepatocyte PPAR γ has little direct impact on DNL, FA oxidation, lipid uptake and TAG export. However, evidence indicates that hepatic PPAR γ plays a primary role in regulating FA uptake, likely through regulating the expression of Cd36, and the MAG pathway, by regulating expression of Mogat1,

which esterifies FA to MAG to form DAG. Impairment of these pathways after the loss of hepatocyte PPAR γ may explain, in part, the protection against age- and diet-induced steatosis.

Materials and methods

Animals

All mouse studies were approved by the IACUC of the Jesse Brown VA Medical Center and performed in accordance with the Guide for the Care and Use of Laboratory Animals. PPAR $\gamma^{\Delta/\Delta}$ (He *et al.* 2003) mice were purchased from Jackson Laboratories (Strain 004584, B3.129-Pparg^{tm2Rev}/J, Bar Harbor, ME) and bred as homozygotes. Animals were housed in a temperature- (22–24°C) and humidity-controlled specific pathogen-free barrier facility with 12-h light/12-h darkness cycle (lights on at 06:00 h). Mice were fed a standard laboratory rodent chow diet (Formulab Diet 5008, Purina Mills, Richmond, IN, USA), unless otherwise indicated. Ten- to twelve-week-old male PPAR $\gamma^{\Delta/\Delta}$ littermate mice were randomized and injected in the lateral tail vein with 100 μ L saline containing 1.5×10^{11} genome copies of an AAV8 bearing either a TBG-driven Cre recombinase (AAV8-TBGp-Cre, Penn Vector Core, University of Pennsylvania), which generates adult-onset hepatocyte (liver)-specific PPAR γ -knockdown mice (aLivPPAR γ kd) or AAV8-TBGp-Null, which generates controls.

Chow-fed mice were killed in the post-absorptive state (4 h after food removal at 07:00 h), at 1 or 18 weeks after PPAR γ knockdown. A separate group of PPAR $\gamma^{\Delta/\Delta}$ mice was fed a low-fat (LF) diet with 10% kcal fat (D12450B, Research Diets, Inc. New Brunswick, NJ, USA) from weaning onward. At 10–12 weeks of age, mice were injected with either AAV8-TBGp-Cre or AAV8-TBGp-Null, and half the mice in each group switched to a nutrient-matched 60% HF diet (D12492, Research Diets, Inc), whereas the remaining mice continued to receive a LF diet. Animals were maintained on their respective diets for 14 weeks and killed in the post-absorptive state.

Mice were killed by decapitation, and trunk blood was collected to determine blood glucose (Alphatrack2, Abbott), plasma insulin (Mercodia, Uppsala, Sweden), TAG, NEFA, cholesterol and 3 β -hydroxybutyrate (Wako Diagnostics) levels following the manufacturer's instructions. Liver and fat sub-depots were weighed. Livers were snap-frozen in liquid nitrogen and stored at –80°C. In a subset of mice killed 1 week after AAV8-TBGp-Null or AAV8-TBGp-Cre injection, multiple tissues were collected to assess AAV8-

TBGp-driven Cre expression. A group of 10- to 12-week-old C57Bl6/J mice was injected with 1.5×10^{11} genome copies of an AAV8-TBGp-EGFP (Cat #AV-8-PV0146, Penn Vector Core, GFP as a reporter gene) and killed 1 week after to collect multiple tissues to assess GFP expression. Also, a piece of liver was fixed in 10% formalin to assess hepatocyte-specific expression of GFP.

Assessment of hepatic lipids

To assess the hepatic TAG content, neutral hepatic lipids were extracted in isopropanol and TAG measured as previously published (Cordoba-Chacon *et al.* 2014a).

To assess hepatic FA composition in mice fed LF and HF diets, total lipids were extracted using the Bligh and Dyer Method (Bligh & Dyer 1959). An aliquot of extracted lipids was transmethylated to quantify specific methyl esters of FA using GC/MS, as we previously reported (Kineman *et al.* 2016).

LC/MS was used to assess the relative content of hepatic TAG, DAG and MAG. Briefly, hepatic homogenates were spiked with standards (50 μ g trionadecadienoin glyceride (TAG-(19:2/19:2/19:2)), 50 μ g dipentadecanoin glyceride (DAG-(15:0/15:0)) and 50 μ g mononadecanoin glyceride (MAG-(19:0)); Nu-Chek, Waterville, MN, USA) and extracted using the Bligh and Dyer Method (Bligh & Dyer 1959). Aliquots were dissolved in 80:19.5:0.5 parts of methanol/chloroform/water to dilute the standards to a concentration of 0.25 μ g/mL. Samples (10 μ L) were injected using an Agilent 2600 UPLC into the AB Sciex 6500 Qtrap mass spectrometer (Agilent Technologies) without chromatography separation. The flow rate of mobile phase (methanol/chloroform/water 80:19.5:0.5 v/v) containing 0.1% of NH₄COOH was set to 200 μ L/min. Electrospray ionization-mass spectrometry (ESI-MS) was performed in positive multiple reaction monitoring (MRM) mode for the quantitative and qualitative analysis. The spray voltage was 4.5 kV, the source temperature was set at 450°C. Mass spectra were acquired and recorded by Analyst software (AB Sciex, version 6.1). The major neutral lipids species known to be present in the liver tissues were analyzed in MRM mode, with the transition from its ammoniated ion (Q1) to the product ion derived from the loss of its ammoniated fatty acid (Q3) (Yang & Subbaiah 2015). Quantification of individual molecular species was performed from the relative intensities of the various species and the corresponding internal standards, respectively. Individual MRM of the internal standards was MAG-(19:0) Q1 390.4, Q3 75.1;

DAG-(15:0/15:0) Q1 558.5, Q3 299.3; TAG-(19:2/19:2/19:2) Q1 938.8, Q3 625.5.

Gene expression analysis

Hepatic and adipose tissue RNA was extracted using TRIzol Reagent (Life Technologies) and treated with RQ1 RNase-free DNase (Promega). DNA-free RNA was transcribed, and qPCR was performed as previously published (Cordoba-Chacon *et al.* 2014a, Kineman *et al.* 2016). qPCR primer sequences for PPAR γ , carnitine palmitoyltransferase 1 α (Cpt1 α), adipose triglyceride lipase (Atgl), hormone-sensitive lipase (Hsl), sterol response element-binding protein 1c (Srebp1c), acetyl-CoA carboxylase 1 (Acc1), fatty acid synthase (Fasn), fatty acid elongase (Elovl6), stearoyl-CoA desaturase 1 (Scd1), fatty acid translocase (Cd36), glycerol phosphate acyltransferase (Gpat1), monoacylglycerol acyltransferase 1 (Mogat1), Cre recombinase, GFP, cyclophilin A, β -actin and hypoxanthine-guanine phosphoribosyltransferase were previously published (Cordoba-Chacon *et al.* 2014a, 2015a, Kineman *et al.* 2016). Primer sequences for PPAR α (NM_011144): Se: GGGAAGACCAGCAACAACC, As: GC AGTGGAAGAATCGGACCT; acyl-CoA synthetase long-chain family member 1 (Acsl1, NM_007981): Se: GAGGGTGAGGTGTGTGTGAAA, As: CCGTGTGTAACC AGCCATCT; hepatic nuclear factor 4 α (Hnf4 α , NM_008261.3): Se: ACATTCGGGCAAAGAAGATTG, As: ACCTGGTCATCCAGAAGGAGTT; PPAR γ co-activator 1 α ; (Pgc1 α , NM_008904.2): Se: TTCCCGATCACCATATT CCA, As: TTCATCCCTCTTGAGCCTTTC; Cyp4a10 (NM_010011.3): Se: CCACTGATTCTGTTGTGGAGC, As: CATTAGAAGAGAGGGGATGAGGA; monoacylglycerol lipase (Mgl1, NM_001166251.1): Se: GTGGAATGCAAAA GCCAAGA, As: AGCTCATCATAACGGCCACA; apolipoprotein B (ApoB, NM_009693.2): Se: AGCCCAGCACTGACTGACTT, As: GAAGCCTTGGGCA CATTG; microsomal triglyceride transfer protein (Mttp, NM_001163457.1): Se: CAGTGGATGCCTCTTTTGTG, As: GTCTCGAATTGCCTGAGTGG; hepatic lipase (Hl, NM_008280.2): Se: TTTTCCTGGTGTCTGCATCT, As: CA GGCGATCGTTTTTCATCTT; low-density lipoprotein lipase receptor (Ldlr, NM_001252658.1): Se: TGTCACCTGTCAGTCCAATCAA, As: TCAGAGCCATCTAGGCAA TCTC; very-low-density lipoprotein receptor (Vldlr, NM_013703.2): Se: GTGCAAGGCAGTAGGCAAAG, As: GCTGAGATCAGCCCCAAAACA; lipoprotein-related protein 1 (Lrp1, NM_008512.2): Se: ACACACGCCAACTG TACCAA, As: TGACATTCGGGTCACAAAACA; monoacylglycerol acyltransferase 2 (Mogat2,

NM_146035.2): Se: TGTGAAAACCTGGAAATCGACA, As: CAGTCTCCAGCATGAAAAATCC; diacylglycerol acyltransferase 1 (Dgat1, NM_010046.2): Se: AGCTGTGGCC TTACTGGTTG, As: AGCAGCCCCACTGACCTT.

Western blot

Livers were homogenized in extraction buffer pH 7.5, 50mM HEPES, 2mM EGTA, 2mM EDTA, 130mM NaCl, 10mM NaF, 20mM β -glycerophosphate, 2mM sodium pyrophosphate, 1mM sodium vanadate, 0.5mM PMSF, 0.1% nonidet P-40, 2mM benzamidine, 1mM TLCK, 10 μ g/mL leupeptin, 10% glycerol, with protease inhibitors (Complete, Roche), followed by sonication for 10s. Protein concentration was determined using Bradford reagent (Bio-Rad Laboratories). 100 μ g of denatured proteins were separated by SDS-PAGE (Mini-PROTEAN TGX Gels 10%, Bio-Rad Laboratories) and transferred to nitrocellulose membranes. Membranes were blocked with 5% nonfat, dry milk in Tris-buffered saline with 0.05% Tween-20 for 1h at 25°C, and then incubated with primary antibodies overnight at 4°C (Rabbit anti-human PPAR γ mAb (C26H12), 1/500; Rabbit anti-human Histone H3 mAb (D1H2), 1/1000 (Cell Signaling Technology)), washed and incubated with secondary antibodies for 2h at 25°C (Goat Anti-Rabbit IgG (H+L)-HRP Conjugate, 1/2000 (Bio-Rad Laboratories)). After washing, SuperSignal WestFemto Maximum Sensitivity Substrate (Thermo Scientific) was added and the light signal was detected and analyzed using a C-Digit Blot Scanner and Image Studio Lite Ver 3.1 (Li-Cor Biosciences, Lincoln, NE, USA).

Immunohistochemistry

Livers were fixed in formalin and paraffin embedded. 5 μ m sections were deparaffinized, hydrated in graded-ethanol/water solutions and then treated with 10mM citrate buffer at 125°C for 5' (GFP, desmin and F4/80 staining) followed by 0.05% porcine trypsin in Tris-buffered solution (TBS) for 10 min at 37°C (F4/80 staining only). Samples were blocked in TBS-containing 1.5% goat serum and 0.01% Tween-20 for 20', and sections were incubated (4°C overnight in TBS 0.01% Tween-20) with mouse anti-GFP, 1:100 Cell Signaling #2955; rabbit anti-desmin, 1:50 Cell Signaling #5332; rat anti-F4/80 1:50 eBiosciences (San Diego, CA, USA) #14-4801-82. Secondary antibodies (1:500 in blocking buffer): goat anti-rabbit IgG Alexa Fluor594 Cell Signaling #8889 (for desmin staining), goat anti-mouse IgG Alexa Fluor594

Cell Signaling #8890 and goat anti-mouse IgG Fluor488 Cell Signaling #4408 (for GFP stainings), goat anti-rat IgG Alexa Fluor488 Cell Signaling #4416 (for F4/80 staining). Sections were mounted with Fluoroshield with DAPI (Sigma-Aldrich) and immunofluorescence was detected using a Olympus BX43 microscope (Olympus). Images were recorded using Olympus CellSens software (Olympus) and processed using ImageJ (NIH) and CellSens (Olympus).

Statistics

Student's *t*-tests were performed to analyze the effect of AAV8-TBGp-Cre on PPAR γ expression in liver, epididymal fat (eWAT) and inguinal fat (iWAT) (Fig. 1G). 2-Way ANOVA, followed by Bonferroni's *post hoc* analysis, was used to determine the effect of aLivPPAR γ kd with age or the effect of aLivPPAR γ kd with diet. *P* values less than 0.05 were considered significant.

All statistical analyses were performed using GraphPad Prism 5 (GraphPad Software).

Results

Validation of hepatocyte-specific expression of TBGp-driven transgene after AAV8 injection

Hepatocyte specificity expression of transgenes delivered by AAV8 and driven by TBG was confirmed using an AAV8-TBGp-EGFP reporter (Fig. 1A, B, C, D and E) that led to GFP-positive staining only in hepatocytes and not in other cell types, including vascular endothelial cells, connective tissue surrounding vessels, cholangiocytes of bile ducts (Fig. 1A and B), hepatic stellate cells (HSC; stained positive (red) for desmin (Fig. 1C)) and macrophages, (stained positive (red) F4/80 (Fig. 1D)). AAV8-TBGp-driven GFP and Cre expression was detected in hepatic but not in extrahepatic tissues

Figure 1

Hepatocyte specificity expression of AAV8-TBGp-driven transgene. Hepatocyte-specific expression of GFP in AAV8-TBGp-EGFP-injected wild-type mice (green, A and B). GFP expression was absent in non-hepatocyte cells (yellow arrows) in sinusoids (Sn), central vein (CV), portal vein (PV), bile duct (BD) or artery (HA). TBGp-GFP was not expressed in hepatic stellate cells (HSC, desmin +, red, C) or macrophages (Mac, F4/80+, red, D). Sections were counterstained with DAPI (blue nuclei, A, B, C and D). Hepatic GFP (E) and Cre (F) expression was detected only in liver extracts of AAV8-TBGp-EGFP- and AAV8-TBGp-Cre-injected mice, respectively. To confirm the hepatocyte-specific activity of Cre recombinase, PPAR $\gamma^{fl/fl}$ mice were injected with AAV8-TBGp-Cre and expression of PPAR γ was reduced in hepatic extracts but not adipose tissue (G). Ctx, cortex; eWAT, epididymal fat; Int, intestine; iWAT, inguinal fat. Asterisks indicate the difference between AAV8-TBGp-Cre-injected mice as compared to AAV8-TBGp-Null mice. **P* < 0.05; ****P* < 0.0001. *n* = 3–6 mice/group.

Figure 2

Adult-onset hepatocyte-specific PPAR γ knockdown (aLivPPAR γ kd) in chow-fed mice (A, B and C) and diet-induced obese mice (D, E and F). (A) PPAR γ ^{fl/fl} mice were injected at 10 weeks of age with 1.5×10^{11} GC AAV8-TBGp-Null (C, open columns) or 1.5×10^{11} GC AAV8-TBGp-Cre (Kd, shaded columns) via lateral tail vein and killed 1 or 18 weeks after. (B) Hepatic PPAR γ mRNA and (C) protein expression of 1 week and 18 weeks aLivPPAR γ kd and their littermate control mice. Representative image of the western blot for hepatic PPAR γ and Histone (as loading control). Of note, nuclear protein variability within total hepatic extracts (assessed by Histone) alters the amount of PPAR γ protein detected. $n = 4-5$ mice/group. (D) LF-fed PPAR γ ^{fl/fl} mice were injected at 10 weeks as described above and immediately half of the mice were fed a high-fat diet (HF, 60% kcal from fat) to induce liver steatosis, whereas the rest were maintained on a low-fat diet (LF, 10% kcal from fat). Mice were killed 14 weeks after. (E) Hepatic PPAR γ mRNA and (F) protein expression of 14 weeks LF- and HF-fed aLivPPAR γ kd and their littermate controls. Representative images of the western blot for hepatic PPAR γ and Histone (as loading control). Asterisks indicate the differences between C and Kd. * $P < 0.05$; *** $P < 0.0001$. Letters indicate the differences between 1 week and 18 weeks or LF- and HF-fed mice within group. $^bP < 0.01$; $^cP < 0.0001$. $n = 5-6$ mice/group.

(Fig. 1E and F). Expression of PPAR γ was reduced in liver but not in adipose tissue (Fig. 1G). Interestingly, a modest increase of PPAR γ expression was detected in eWAT of aLivPPAR γ kd mice.

Effects of hepatocyte-specific PPAR γ knockdown on metabolic endpoints in adult mice (aLivPPAR γ kd)

After 1 and 18 weeks of chow diet AAV8-TBGp-Cre injection resulted in a clear knockdown of hepatocyte PPAR γ mRNA and protein at 1 week after injection that persisted after 18 weeks of AAV8 injection (Fig. 2A, B and C). Mouse PPAR γ gene produces two isoforms PPAR γ 1 and PPAR γ 2 (NM_001127330.2 and NM_0111463). Three mRNA variants are described for PPAR γ 1 (variant 1: NM_001127330.2; variant 3: NM_001308352.1; variant 4: NM_001308354.1), but all encode for the same protein (isoform 1). In PPAR γ ^{fl/fl} mice two exons, previously described as exons 1 and 2 (He *et al.* 2003), are flanked by loxP sites. These

exons span 227 and 169bp respectively are located within the CDS of each variant and the qPCR primers employed in this study are placed in these two exons. Therefore, the qPCR result of PPAR γ gene expression accounts for all variants and thereby the western blot results account for both isoforms. Of note, hepatic PPAR γ mRNA levels modestly, but significantly, increased with age in control but not aLivPPAR γ kd mice (Fig. 2B and C).

To assess if hepatic lipid metabolism was altered in chow-fed aLivPPAR γ kd mice, we measured whole body, liver and adipose tissue (unilateral epididymal, inguinal and retroperitoneal fat depots) weights, hepatic TAG levels, as well as circulating blood glucose, plasma insulin, ketones, TAG, NEFA and cholesterol (Table 1). For the majority of endpoints examined, aLivPPAR γ kd had no effect in either age group. However, there was an overall inhibitory effect of aLivPPAR γ kd on hepatic TAG levels ($P = 0.0185$), indicating hepatic PPAR γ plays a role in hepatic lipid accumulation, even under standard feeding conditions.

Table 1 Impact of aLivPPAR γ kd on body, liver and fat depot (sum of the unilateral epididymal, inguinal and retroperitoneal fat depot) weight, hepatic TAG levels and circulating metabolic endpoints (blood glucose, plasma insulin, ketones, TAG, NEFA and NEFA), in chow-fed (top, 1 week and 18 weeks) and LF/HF-fed (bottom, 14 weeks) aLivPPAR γ kd mice and their littermate controls.

		1 week aLivPPAR γ kd – chow diet				18 weeks aLivPPAR γ kd – chow diet				Overall effect (P value) of	
		Control		aLivPPAR γ kd		Control		aLivPPAR γ kd		Age	aLivPPAR γ kd
		Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM		
Body weight	g	25.36 $\pm$ 0.84		24.6 $\pm$ 0.64		31.81 ^b $\pm$ 1.88		32.49 ^c $\pm$ 0.6		<0.0001	0.9719
Liver	g/g BW	0.045 $\pm$ 0.0008		0.043 $\pm$ 0.0022		0.038 ^a $\pm$ 0.0011		0.038 $\pm$ 0.0021		<0.0022	0.3959
Fat mass	g/g BW	0.015 $\pm$ 0.0015		0.013 $\pm$ 0.0011		0.029 ^a $\pm$ 0.0066		0.023 $\pm$ 0.0031		0.0091	0.268
Hepatic TAG	mg/g	47.63 $\pm$ 6.987		38.63 $\pm$ 3.027		50.36 $\pm$ 4.611		34.72 $\pm$ 3.653		0.9024	0.0185
Blood glucose	mg/dL	187 $\pm$ 14.77		176.8 $\pm$ 18.87		190.4 $\pm$ 15.7		199.7 $\pm$ 8.92		0.3797	0.9748
Plasma insulin	ng/ μ L	1.59 $\pm$ 0.15		1.69 $\pm$ 0.12		1.88 $\pm$ 0.37		1.34 $\pm$ 0.14		0.8925	0.3323
Plasma ketones	μ M	372.1 $\pm$ 62.194		372.1 $\pm$ 57.92		153.9 ^a $\pm$ 40.907		226.1 $\pm$ 33.635		0.0017	0.4704
Plasma TAG	mg/dL	91.26 $\pm$ 3.772		83.95 $\pm$ 5.728		61.35 $\pm$ 12.607		67.25 $\pm$ 10.736		0.022	0.9396
Plasma NEFA	mEq/L	1.05 $\pm$ 0.038		1.12 $\pm$ 0.063		1.06 $\pm$ 0.095		1.07 $\pm$ 0.064		0.7687	0.5581
Plasma cholesterol	mg/dL	104.83 $\pm$ 5.568		107.83 $\pm$ 5.233		116.17 $\pm$ 8.003		116.61 $\pm$ 5.334		0.1177	0.7812
		14 weeks aLivPPAR γ kd – LF diet				14 weeks aLivPPAR γ kd – HF diet				Overall effect (P value) of	
		Control		aLivPPAR γ kd		Control		aLivPPAR γ kd		Diet	aLivPPAR γ kd
		Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM		
Body weight	g	30.88 $\pm$ 0.95		29.65 $\pm$ 0.6		49.52 ^c $\pm$ 0.55		48.52 ^c $\pm$ 1.13		<0.0001	0.1827
Liver	g/g BW	0.0376 $\pm$ 0.0007		0.0373 $\pm$ 0.0006		0.049 ^c $\pm$ 0.001		0.032 ^{b***} $\pm$ 0.002		0.0062	<0.0001
Fat mass	g/g BW	0.0313 $\pm$ 0.0035		0.0296 $\pm$ 0.0032		0.055 ^c $\pm$ 0.0024		0.065 ^c $\pm$ 0.002		<0.0001	0.1564
Hepatic TAG	mg/g	37.13 $\pm$ 9.114		41.27 $\pm$ 9.188		326.25 ^c $\pm$ 16.654		111.37 ^{b***} $\pm$ 18.11		<0.0001	<0.0001
Blood glucose	mg/dL	182.6 $\pm$ 20.78		187.2 $\pm$ 9.14		218 $\pm$ 15.12		231.2 $\pm$ 12.31		0.0128	0.5449
Plasma insulin	ng/ μ L	1.39 $\pm$ 0.11		1.96 $\pm$ 0.3		11.27 ^c $\pm$ 0.85		9.39 ^c $\pm$ 1.68		<0.0001	0.45
Plasma ketones	μ M	232.3 $\pm$ 42.17		215.4 $\pm$ 30.85		348.71 $\pm$ 22.787		215.41 ^a $\pm$ 31.53		0.0886	0.0323
Plasma TAG	mg/dL	52.78 $\pm$ 7.716		57.18 $\pm$ 7.479		35.8 $\pm$ 3.672		40.83 $\pm$ 4.21		0.0138	0.4479
Plasma NEFA	mEq/L	1.17 $\pm$ 0.05		1.1 $\pm$ 0.08		0.53 ^b $\pm$ 0.07		1.15 ^{**} $\pm$ 0.2		0.0221	0.034
Plasma cholesterol	mg/dL	117.71 $\pm$ 12.99		104.57 $\pm$ 9.2		212.86 ^b $\pm$ 37.85		110.29 ^{**} $\pm$ 8.35		0.0177	0.0078

Superscript letters indicate differences between 1 week and 18 weeks or LF- and HF-fed mice within group. ^a P <0.05; ^b P <0.01; ^c P <0.0001. Asterisks indicate the differences between control and aLivPPAR γ kd mice. * P <0.05; ** P <0.01; *** P <0.0001. n =4–6 mice/group.

After 14 weeks of LF or HF diet To further explore if hepatic lipid accumulation induced by excess dietary fat intake is altered by aLivPPAR γ kd, we fed a HF- or a nutrient-matched LF control diet to aLivPPAR γ kd mice and their littermate controls. After 14 weeks of either LF or HF feeding (Fig. 2D) hepatic PPAR γ mRNA/protein expression remained suppressed in aLivPPAR γ kd mice, compared to controls (Fig. 2E and F).

Consistent with previous reports (Inoue *et al.* 2005, Moran-Salvador *et al.* 2011, Yamazaki *et al.* 2011), HF feeding in control mice increased hepatic PPAR γ expression, compared to those fed a LF diet (Fig. 2E and F). Also, in control mice, HF feeding increased body, liver and fat mass weight and elevated hepatic TAG content and plasma glucose, insulin and cholesterol levels, but plasma TAG and NEFA were reduced (Table 1). Although TAG and NEFA are reported to be elevated in HF-fed mice after an overnight fast, in the post-absorptive state (4-h fasted mice at 11:00h), TAG and NEFA levels are reported to be

reduced (Guo *et al.* 2009, Obrowsky *et al.* 2013, Cordoba-Chacon *et al.* 2014b, 2015b, Horakova *et al.* 2016), likely due to elevated insulin levels under these conditions.

aLivPPAR γ kd, in LF-fed mice, did not impact any of the metabolic endpoints examined (Table 1), including food intake (data not shown). However, HF-fed aLivPPAR γ kd mice showed reduced relative liver weight, and this was associated with a reduced hepatic TAG content (Table 1). Despite reduced hepatic TAG levels, there were no differences in post-absorptive blood glucose, plasma insulin and TAG levels in HF-fed aLivPPAR γ kd mice, compared to diet-matched controls (Table 1). However, normal glucose and insulin levels in the post-absorptive mouse may not be indicative of the whole-body glucose homeostasis, which requires dynamic evaluation by glucose and insulin tolerance tests. Of note, plasma ketones and cholesterol were reduced in HF-fed aLivPPAR γ kd mice, whereas plasma NEFAs were increased as compared to HF-fed control littermates (Table 1).

Figure 3

Impact of aLivPPAR γ kd on hepatic gene expression of molecular mechanisms controlling hepatic TAG levels. (A) 1-week (top) and 18-week (bottom) chow-fed and (B) 14-week LF-fed (top) and HF-fed (bottom) aLivPPAR γ kd-induced regulation of hepatic gene expression. Graphs represent the natural logarithm of the relative change in the gene expression of aLivPPAR γ kd mice as compared to their littermates controls (set at 0, x-axis), within age (A) or diet (B). Absolute values are included in [Supplementary Table 1A](#) and [B](#). Asterisks show significant changes between C and aLivPPAR γ kd within age (A) or diet (B). * $P < 0.05$; ** $P < 0.01$; *** $P < 0.0001$. Livers were collected at 11:00h (4h after food removal). DNL, *de novo* lipogenesis; FA $_{ox}$, fatty acid oxidation; TAG $_{hydr}$, TAG hydrolysis; VLDL $_{syn}$, VLDL synthesis; TAG $_{syn}$, TAG synthesis. Selected genes of these metabolic pathways represented in [Fig. 3](#): peroxisome proliferator-activated receptor α (PPAR α), acyl-CoA synthetase long-chain family member 1 (Acs11), carnitine palmitoyltransferase 1 α (Cpt1 α), hepatic nuclear factor 4 α (Hnf4 α), PPAR γ co-activator 1 α (Pgc1 α), Cyp4a10, adipose triglyceride lipase (Atgl), hormone-sensitive lipase (Hsl), monoacylglycerol lipase (Mgl1), apolipoprotein B (ApoB), microsomal triglyceride transfer protein (Mttp), sterol response element-binding protein 1c (Srebp1c), acetyl-CoA carboxylase 1 (Acc1), fatty acid synthase (Fasn), fatty acid elongase (Elovl6), stearoyl-CoA desaturase 1 (Scd1), hepatic lipase (Hsl), low-density lipoprotein lipase receptor (Ldlr), very-low-density lipoprotein receptor (Vldlr), lipoprotein-related protein 1 (Lrp1), fatty acid translocase (Cd36), glycerol phosphate acyltransferase (Gpat1), monoacylglycerol acyltransferase 1 or 2 (Mogat1/2), diacylglycerolacyltransferase 1/2 (Dgat1/2).

Association between aLivPPAR γ kd-mediated alterations in hepatic gene expression and metabolic endpoints

It has been previously reported that congenital liver-specific knockout of PPAR γ alters the expression of a number of genes related to the regulation of hepatic TAG levels ([Gavrilova et al. 2003](#), [Matsusue et al. 2003](#), [Moran-Salvador et al. 2011](#)). However, from these studies, it is difficult to determine which changes may be due to the direct actions of hepatocyte PPAR γ and which may be altered by secondary changes that occur overtime. Therefore, qPCR was used to screen changes in expression of key genes related to fatty acid oxidation, intrahepatic TAG hydrolysis, hepatic TAG export, DNL, hepatic lipid uptake and TAG synthesis, in liver samples from chow-fed (1 and 18 weeks after aLivPPAR γ kd, [Fig. 3A](#)) and LF- and HF-fed (14 weeks after aLivPPAR γ kd, [Fig. 3B](#)) mice. The data shown in [Fig. 3](#) are expressed as fold-change in hepatic gene expression in aLivPPAR γ kd mice, compared to PPAR γ -intact controls (set at 0), within age and diet, whereas [Supplementary Table 1A](#) and [B](#) (see section on

[supplementary data](#) given at the end of this article) provides absolute values. There were small, but significant changes in the expression of a number of genes in aLivPPAR γ kd mice, compared to PPAR γ -intact controls within specific groups. However, collective examination of this data set provides insight into which genes (pathways) are major targets of PPAR γ , that could explain why aLivPPAR γ kd protects against hepatic fat accumulation.

***De novo* lipogenesis** Although experimental evidence suggests that hepatocyte PPAR γ promotes liver fat accumulation by regulating the expression of genes important for DNL ([Matsusue et al. 2003, 2014](#)), aLivPPAR γ kd did not significantly reduce the expression of DNL genes (Srebp1c, Acc1, Fasn, Elovl6, Scd1) across age or diet. However, we could not exclude the fact aLivPPAR γ kd could indirectly mediate the activity of DNL enzymes, independent of changes in gene expression. Therefore, to estimate the impact of aLivPPAR γ kd on hepatic DNL, we used GC/MS to measure FA composition in livers of mice fed either a LF or HF diet. [Supplementary Table 2](#) provides

Figure 4

aLivPPAR γ kd reduces HF diet-induced FA levels, but has little impact on FA indices of DNL. (A) Hepatic FA levels of 16:0, palmitate; 16:1, palmitoleate; and 18:2, linoleate levels and (B) hepatic FA ratios indicative of DNL include the SCD index (16:1/16:0) and the DNL index (16:0/18:2), where control (open columns, C) and aLivPPAR γ kd (closed columns, Kd) mice were fed a LF or a HF diet for 14 weeks. Asterisks indicate differences between C and Kd. *** $P < 0.0001$. Letters indicate differences between LF- and HF-fed mice within group. $^aP < 0.05$; $^cP < 0.0001$. $n = 4-6$ mice/group.

data for all FA detected, whereas Fig. 4A shows absolute levels of palmitic acid (16:0), palmitoleic acid (16:1(n-7)) and linoleic acid (18:2(n-6)). The absolute levels of these FAs were significantly reduced in HF-fed aLivPPAR γ kd mice as compared to HF-fed controls, consistent with the reduction in hepatic TAG content. Specific ratios of these FA (Fig. 4B) have been shown to be indicative of DNL (SCD-1 index 16:1/16:0) and DNL index, 16:0/18:2 (Sevastianova *et al.* 2012, Silbernagel *et al.* 2012, Lee *et al.* 2015, Kineman *et al.* 2016). As previously reported, HF diet reduces the rate of DNL (Duarte *et al.* 2014) and expression of DNL proteins (Benard *et al.* 2016), as reflected by significant reduction in both the SCD-1 and DNL index, as well as the reduction in DNL gene expression (Acc1, Fasn, Elovl6 and Scd1; Supplementary Table 1B). Independent of diet, loss of hepatocyte PPAR γ did not influence these indices (Fig. 4B). Taken together, these results suggest that hepatic PPAR γ plays a minimal role in directly regulating hepatic DNL.

Hepatic TAG export, FA oxidation and lipid uptake A reduction in hepatic fat content observed in aLivPPAR γ kd mice could be due to an increased rate

of hepatic VLDL production or a decreased rate of TAG lipoprotein clearance. However, examination of genes critical for these processes were not consistently altered by aLivPPAR γ kd (Fig. 3) and circulating TAG in aLivPPAR γ kd did not differ from PPAR γ -intact controls, within age and diet group (Table 1). It could also be possible that the reduced TAG content observed in livers of aLivPPAR γ kd mice is due to an increase in intrahepatic TAG hydrolysis and FA oxidation. However, the fact that the expressions of Atgl, Hsl, Mgl, PPAR α , Acs1, Cpt1 α , Hnf4 α , Pgc1 α and Cyp4a10 were not increased across groups (Fig. 3), whereas HF-aLivPPAR γ kd mice exhibited a decrease in plasma ketones (Table 1), suggests that hepatic FA oxidation is actually reduced. It is possible that this reduction in FA oxidation/ketogenesis is secondary to a reduction in intrahepatic FA availability due to a reduction in FA uptake as aLivPPAR γ kd reduced the expression of hepatic Cd36 (FA translocase), where this was associated with an increase in circulating NEFA in HF-fed mice (Table 1). In fact, Cd36 has been previously shown to be a PPAR γ target gene (Tontonoz *et al.* 1998). However, it should be noted that a significant reduction in Cd36 was not

Figure 5

aLivPPAR γ kd reduces HF diet-induced hepatic TAG and DAG levels, whereas increasing MAG levels, independent of diet, indicative of impaired hepatic MAG pathway activity in aLivPPAR γ kd mice. (A) Schematic representation of acylglycerol synthesis by glycerol-3-phosphate (G3P) pathway that produces DAG by subsequent re-esterification of FA in G3P and lysophosphatidic acid (LPA) or by monoacylglycerol (MAG) pathway that produces DAG after re-esterification of FA in MAG. (B) Relative hepatic TAG, DAG and MAG levels assessed by liquid chromatography/mass spectrometry (LC/MS) in control (open columns) and aLivPPAR γ kd (close columns) mice. TAG, DAG and MAG are shown as relative values of LF-fed controls. Asterisks indicate differences between control and aLivPPAR γ kd. *** $P < 0.0001$. Letters indicate differences between LF- and HF-fed mice within group. $^bP < 0.01$; $^cP < 0.0001$. $n = 5-6$ mice/group.

observed in aLivPPAR γ kd after 1 week of knockdown, or in LF-fed mice, suggesting that under these conditions, the low level of PPAR γ is not sufficient to maintain Cd36 expression or that the full expression requires additional factors that are activated with age or diet, such as LXR and PXR (Zhou *et al.* 2008).

TAG synthesis TAG, DAG and MAG are generated by esterification of newly synthesized FA or extrahepatic FA into acylglycerol backbones, as illustrated in Fig. 5A. In the liver, it is thought that the primary source of TAG is via the glycerol-3-phosphate (G3P) pathway, that generates DAG (Coleman & Mashek 2011, Mashek 2013), which serves as a substrate of DAG transferases 1 and 2 (Dgat1/2). However, it is becoming evident that the MAG pathway (i.e. generation of DAG from MAG via MAG transferases 1 and 2 (Mogat1/2 in mice)), may be a relevant pathway in NAFLD (Hall *et al.* 2012, Mashek 2013). Examination of the expression of the key genes involved in TAG synthesis revealed that there was an overall inhibitory effect of aLivPPAR γ kd on the expression of Mogat1 (Supplementary Table 1) that reached significance with age and HF feeding (Fig. 3B), without a reduction in Gpat, Mogat2, Dgat1 or Dgat2 expression (Fig. 3B). Of note, Mogat1 has been reported to be a direct target of PPAR γ (Lee *et al.* 2012, Yu *et al.* 2015) and in fact, expression of Mogat1 increases with age and HF feeding, P value:

0.0063 and <0.0001 , respectively, (Supplementary Table 1A and B), mirroring the relative changes observed in hepatic PPAR γ expression (Fig. 2). To indirectly test if the reduction in Mogat1 gene expression translated into a reduction in MAG pathway activity, we used LC/MS to measure the relative levels of MAG, DAG and TAG in LF- and HF-fed mice with or without hepatic PPAR γ . Overall, aLivPPAR γ kd increased MAG levels, which reached significance in LF-fed mice. In HF-fed aLivPPAR γ kd mice, this was associated with a decrease in DAG and TAG (Fig. 5B). Interestingly, in LF-fed aLivPPAR γ kd, the relative levels of DAG and TAG were not altered. Taken together, loss of hepatocyte PPAR γ signaling preferentially reduces the esterification of FA by direct transcriptional regulation of the MAG pathway, where loss of this effect could contribute to the protection against excess TAG accumulation observed in aLivPPAR γ kd mice.

Discussion

Hepatocyte PPAR γ has been defined as a steatogenic factor (Rahimian *et al.* 2001, Gavrilova *et al.* 2003, Matsusue *et al.* 2003, Inoue *et al.* 2005, Moran-Salvador *et al.* 2011, Pettinelli & Videla 2011), whereas others suggest that its activation decreases hepatic steatosis (Belfort *et al.* 2006, Ratzu *et al.* 2008, Sanyal *et al.* 2010). The fact that PPAR γ is the target of TZDs that are used in

the treatment of diabetes and NAFLD raises the question if the hepatic-specific agonism of PPAR γ is well understood (Ahmadian *et al.* 2013). Therefore, we sought to determine which molecular processes are the primary targets for hepatocyte PPAR γ that promotes TAG accumulation. We have taken advantage of the novel adult-onset, hepatocyte-specific PPAR γ knockdown (aLivPPAR γ kd) model that allowed us to study the early events altered by aLivPPAR γ kd (1 week of knockdown), and how this deficit influences liver function overtime under different dietary conditions. Our approach has benefits over existing congenital knockout models because it avoids compensatory changes that could occur with embryonic knockout and therefore better models the consequence of manipulating PPAR γ function in adults, where NAFLD/NASH typically develops. As discussed in detail below, our primary findings are that hepatic PPAR γ has minimal direct effects on hepatic DNL, TAG uptake, TAG export or FA oxidation, but plays a major role in upregulating genes/pathways critical for hepatic FA uptake- and MAG pathway-mediated FA esterification.

Congenital hepatocyte-specific PPAR γ knockout has been reported to be associated with a reduction of hepatic expression of genes critical for DNL (Gavrilova *et al.* 2003, Matsusue *et al.* 2003, Yu *et al.* 2003, Moran-Salvador *et al.* 2011). Also, use of antisense oligonucleotide strategy to suppress elevated hepatic PPAR γ in apoB/BATless mice, reduced hepatic TAG accumulation, as well as the expression of DNL genes and DNL rate as assessed by $^3\text{H}_2\text{O}$ incorporation into TAG-associated FA (Zhang *et al.* 2006). In addition, overexpression of PPAR γ in a hepatic cell line (AML-12; Schadinger *et al.* 2005) was shown to increase SREBP1c and Fasn expression that was associated with an increase in ^{14}C -acetate incorporation into TAG. Finally, overexpression of PPAR γ in some (Yu *et al.* 2003), but not all (Bai *et al.* 2011) *in vivo* models, increased the expression of genes associated with DNL. In contrast to these reports, in the aLivPPAR γ kd model system, expression of DNL genes were not suppressed in any conditions tested, consistent with the lack of an effect on DNL indices (16:1/16:0 and 16:0/18:2). In fact, we have recently reported that although PPAR γ expression was associated with TAG accumulation in a model of DNL-generated steatosis (Kineman *et al.* 2016), adult-onset hepatic PPAR γ knockdown in this steatotic model did not reduce hepatic TAG content or FA indices of DNL (Cordoba-Chacon *et al.* 2015a). The question arises, why are our current results counter to that previously reported by others? We might speculate that any changes observed in the expression of DNL genes in congenital liver-specific

PPAR γ -knockout models could be secondary to changes that occur due to compensation during development or systemic metabolic changes that occur overtime. Also, the use of antisense oligonucleotides (ASO) to acutely suppress enhanced PPAR γ expression *in vivo* (Zhang *et al.* 2006) is not a hepatocyte-specific approach, and therefore, a reduction in PPAR γ in other cell types could contribute to the phenotype observed. Finally *in vivo* (Zhang *et al.* 2006) or *in vitro* (Schadinger *et al.* 2005) overexpression of PPAR γ may have off-target effects. Therefore, we can conclude that in the context of adult metabolic function, loss of hepatic PPAR γ does not directly control hepatic DNL.

Early work by Gavrilova and coworkers and Matsusue and coworkers who crossbred the congenital liver-specific PPAR γ model with a lipodystrophic model (AZIP; Gavrilova *et al.* 2003), and ob/ob mice (Matsusue *et al.* 2003), respectively, observed a reduction in hepatic TAG content associated with elevated plasma TAG and thus concluded that hepatic PPAR γ was critical to maintain hepatic TAG uptake. However, in chow-fed WT mice (Matsusue *et al.* 2003, Moran-Salvador *et al.* 2011) and HF-fed (Moran-Salvador *et al.* 2011) mice with congenital liver-specific PPAR γ knockout, as well as in our HF-fed aLivPPAR γ kd model, circulating TAG did not differ from PPAR γ -intact controls, despite the dramatic reduction in hepatic TAG content. Also, there were no decreases in the expression of genes known to be critical in hepatic TAG uptake in mouse livers, including low-density lipoprotein receptor (Ldlr; Ishibashi *et al.* 1994, Havel & Hamilton 2004) and hepatic lipase (HL; Havel & Hamilton 2004, Freeman *et al.* 2007). However, it should be noted that the expression of very low-density lipoprotein receptor (Vldlr), a known PPAR γ target in adipocytes (Tao *et al.* 2010), was significantly reduced in HF-fed aLivPPAR γ kd mice. The expression of hepatic Vldlr is normally low, but is increased in mouse models of fatty liver (also observed with HF feeding in this study, see Supplementary Table 1), and whole-body knockout of Vldlr reduces ER stress and HF diet-induced hepatic steatosis (Jo *et al.* 2013). However, a liver-specific role of Vldlr in hepatic TAG uptake remains to be determined. Although the role of PPAR γ in regulating hepatic TAG uptake remains to be further explored, our current results coupled with previous reports, do provide compelling evidence that hepatic PPAR γ promotes hepatic FA uptake by regulating the expression of Cd36. Specifically, in both aged and HF-fed aLivPPAR γ kd mice, expression of Cd36 was reduced. Cd36 has been shown to be a direct target of PPAR γ (Tontonoz *et al.* 1998) and its

expression is increased in steatotic livers. In the current study, a reduction in Cd36 levels in aLivPPAR γ kd mice was only observed with age or HF feeding, consistent with the fact that in addition to PPAR γ , LXR and PXR are also required for the full expression of Cd36 (Zhou *et al.* 2008). Although global Cd36 knockout does not protect against high fructose-induced hepatic steatosis (Hajri *et al.* 2002) or prevent fatty liver in ob/ob mice (Nassir *et al.* 2013), a more recent report supports a liver-specific role of Cd36 in FA uptake. Specifically, congenital liver-specific Cd36 knockout reduced steatosis in liver-specific Jak2 knockout mice that led to an increase in plasma NEFA (Wilson *et al.* 2015). Also in that same study, liver-specific Cd36-knockout mice with intact hepatic Jak2, dramatically reduced HF diet-induced steatosis that was associated with a reduction in hepatic FA uptake as measured by hepatic accumulation of BODIPY-FA *in vivo* (Wilson *et al.* 2015). However, loss of hepatic Cd36 did not entirely prevent hepatic FA uptake, which could be mediated by other facilitated transport mechanisms or passive diffusion (Glatz *et al.* 2010), indicating the reduction in CD36 after aLivPPAR γ kd is only in part responsible for the reduction in hepatic TAG content.

Of the selected genes examined in this study, the expression of Mogat1 was the most sensitive to PPAR γ loss. As previously reported, the expression of Mogat1 in the lean mouse liver is low, but increases in association with TAG accumulation, similar to that observed for PPAR γ (Lee *et al.* 2012, Hall *et al.* 2014, Soufi *et al.* 2014, Yu *et al.* 2016), as we also observed in the current study. In addition, hepatic expression of Mogat1, as well as PPAR γ , is elevated in humans with NAFLD (Hall *et al.* 2012, Yu *et al.* 2015). There is an ongoing debate regarding the physiologic role hepatic Mogat1 plays in TAG synthesis as it was originally thought that the glycerol-3-phosphate pathway, not the MAG pathway, is the dominant route to form TAG in the liver (Coleman & Mashek 2011, Mashek 2013). In fact, one laboratory could not detect hepatic MOGAT activity (Cortes *et al.* 2009) and recently reported that global Mogat1 knockout in the ob/ob or Agpat2KO mice did not impact steatosis (Agarwal *et al.* 2016). However, hepatic MOGAT activity has been detected by other laboratories (Yen *et al.* 2002, Hall *et al.* 2012). Importantly, the increase in Mogat1 expression observed in HF-fed and ob/ob mice is associated with an elevation of hepatic MOGAT activity, which is reduced by Mogat1 ASO ip treatment (Hall *et al.* 2014, Soufi *et al.* 2014). The Mogat1-ASO injections reduced hepatic TAG accumulation in one study (Soufi *et al.* 2014), but not the

other (Hall *et al.* 2014). However, it was acknowledged that the knockdown of Mogat1 was not hepatocyte specific, and actually led to a reduction in Mogat1 expression in the adipose tissue that could offset any hepatocyte-specific effect (Soufi *et al.* 2014). In strong support of a physiologic role of hepatic Mogat1 in maintaining hepatic TAG levels, adenoviral shRNA-Mogat1 delivery (that is preferentially taken up by the liver) (Lee *et al.* 2012), and nonviral siRNA-Mogat1 delivery (Hayashi *et al.* 2014), reduced Mogat1 expression and hepatic TAG levels in HF-fed mice. The results of the present study indicate that PPAR γ is necessary to maintain Mogat1 activity, as well as Mogat1 expression, based on the increase in hepatic MAG levels in aLivPPAR γ kd mice. Interestingly, it has been postulated that Mogat1 may prefer extrahepatic (dietary FA) over those produced by hepatic DNL, to synthesize DAG (Steneberg *et al.* 2015). This would be consistent with our observation that although MAG levels were increased in LF-fed aLivPPAR γ kd mice, DAG and TAG levels were normal, where in this context, hepatic DAG and TAG are mainly derived from DNL. However, in HF-fed aLivPPAR γ kd mice (where the bulk of FA is coming from the diet), a reduction in DAG and TAG levels was observed.

Taken together, results suggest that hepatocyte PPAR γ expression in adult livers is not essential to maintain the expression of DNL genes, but it is essential to induce the expression of genes important in hepatic FA uptake (Cd36) and re-esterification (Mogat1). Certainly, other pathways may be mediated by hepatic PPAR γ that were not revealed by our targeted approach. Nonetheless, our current data, coupled with previous reports suggest that impairment of the Cd36-mediated FA uptake and FA esterification by MAG pathway could explain in part the protection against steatosis observed in aLivPPAR γ kd mice.

Supplementary data

This is linked to the online version of the paper at <http://dx.doi.org/10.1530/JOE-16-0447>.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by Department of Veterans Affairs, Office of Research and Development Merit Award (BX001090, BX001114), National Institutes of Health (R21AT008457, S10OD010660, R01DK088133), Chicago Biomedical Consortium with support from the Searle Funds at The

Chicago Community Trust (PDR-033), Pilot Grant through UIC CCTS (NIH-UL1TR000050), West Side Institute for Science and Education (WISE), and 2014 Endocrine Scholar Award in Growth Hormone Research (Endocrine Society).

References

- Agarwal AK, Tunison K, Dalal JS, Yen CL, Farese RV Jr, Horton JD & Garg A 2016 Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2 $^{-/-}$) or obese (ob/ob) mice. *Journal of Lipid Research* **57** 616–630. (doi:10.1194/jlr.M065896)
- Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M & Evans RM 2013 PPAR γ signaling and metabolism: the good, the bad and the future. *Nature Medicine* **19** 557–566. (doi:10.1038/nm.3159)
- Ashpole NM, Herron JC, Mitschelen MC, Farley JA, Logan S, Yan H, Ungvari Z, Hodges EL, Csiszar A, Ikeno Y, *et al.* 2016 IGF-1 regulates vertebral bone aging through sex-specific and time-dependent mechanisms. *Journal of Bone and Mineral Research* **31** 443–454. (doi:10.1002/jbmr.2689)
- Bai L, Jia Y, Viswakarma N, Huang J, Vluggens A, Wolins NE, Jafari N, Rao MS, Borensztajn J, Yang G, *et al.* 2011 Transcription coactivator mediator subunit MED1 is required for the development of fatty liver in the mouse. *Hepatology* **53** 1164–1174. (doi:10.1002/hep.24155)
- Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, Balas B, Gastaldelli A, Tio F, Pulcini J, *et al.* 2006 A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *New England Journal of Medicine* **355** 2297–2307. (doi:10.1056/NEJMoa060326)
- Benard O, Lim J, Apontes P, Jing X, Angeletti RH & Chi Y 2016 Impact of high-fat diet on the proteome of mouse liver. *Journal of Nutritional Biochemistry* **31** 10–19. (doi:10.1016/j.jnutbio.2015.12.012)
- Beysen C, Murphy EJ, Nagaraja H, Decaris M, Riiff T, Fong A, Hellerstein MK & Boyle PJ 2008 A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. *Journal of Lipid Research* **49** 2657–2663. (doi:10.1194/jlr.M800165-JLR200)
- Bligh EG & Dyer WJ 1959 A rapid method of total lipid extraction and purification. *Canadian Journal of Biochemistry and Physiology* **37** 911–917. (doi:10.1139/o59-099)
- Browning JD & Horton JD 2004 Molecular mediators of hepatic steatosis and liver injury. *Journal of Clinical Investigation* **114** 147–152. (doi:10.1172/JCI200422422)
- Coleman RA & Mashek DG 2011 Mammalian triacylglycerol metabolism: synthesis, lipolysis, and signaling. *Chemical Reviews* **111** 6359–6386. (doi:10.1021/cr100404w)
- Cordoba-Chacon J, Gahete MD, McGuinness OP & Kineman RD 2014a Differential impact of selective GH deficiency and endogenous GH excess on insulin-mediated actions in muscle and liver of male mice. *American Journal of Physiology: Endocrinology and Metabolism* **307** E928–E934. (doi:10.1152/ajpendo.00420.2014)
- Cordoba-Chacon J, Gahete MD, Pokala NK, Geldermann D, Alba M, Salvatori R, Luque RM & Kineman RD 2014b Long- but not short-term adult-onset, isolated GH deficiency in male mice leads to deterioration of beta-cell function, which cannot be accounted for by changes in beta-cell mass. *Endocrinology* **155** 726–735. (doi:10.1210/en.2013-1825)
- Cordoba-Chacon J, Majumdar N, List EO, Diaz-Ruiz A, Frank SJ, Manzano A, Bartons R, Puchowicz M, Kopchick JJ & Kineman RD 2015a Growth hormone inhibits hepatic de novo lipogenesis in adult mice. *Diabetes* **64** 3093–3103. (doi:10.2337/db15-0370)
- Cordoba-Chacon J, Majumdar N, Pokala NK, Gahete MD & Kineman RD 2015b Islet insulin content and release are increased in male mice with elevated endogenous GH and IGF-I, without evidence of systemic insulin resistance or alterations in beta-cell mass. *Growth Hormone and IGF Research* **25** 189–195. (doi:10.1016/j.gthr.2015.04.002)
- Cortes VA, Curtis DE, Sukumaran S, Shao X, Parameswara V, Rashid S, Smith AR, Ren J, Esser V, Hammer RE, *et al.* 2009 Molecular mechanisms of hepatic steatosis and insulin resistance in the AGPAT2-deficient mouse model of congenital generalized lipodystrophy. *Cell Metabolism* **9** 165–176. (doi:10.1016/j.cmet.2009.01.002)
- Duarte JA, Carvalho F, Pearson M, Horton JD, Browning JD, Jones JG & Burgess SC 2014 A high-fat diet suppresses de novo lipogenesis and desaturation but not elongation and triglyceride synthesis in mice. *Journal of Lipid Research* **55** 2541–2553. (doi:10.1194/jlr.M052308)
- Freeman L, Amar MJ, Shamburek R, Paigen B, Brewer HB Jr, Santamarina-Fojo S & Gonzalez-Navarro H 2007 Lipolytic and ligand-binding functions of hepatic lipase protect against atherosclerosis in LDL receptor-deficient mice. *Journal of Lipid Research* **48** 104–113. (doi:10.1194/jlr.M600321-JLR200)
- Furnsinn C & Waldhauser W 2002 Thiazolidinediones: metabolic actions in vitro. *Diabetologia* **45** 1211–1223. (doi:10.1007/s00125-002-0899-1)
- Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ & Reitman ML 2003 Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. *Journal of Biological Chemistry* **278** 34268–34276. (doi:10.1074/jbc.M300043200)
- Glatz JF, Luiken JJ & Bonen A 2010 Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. *Physiological Reviews* **90** 367–417. (doi:10.1152/physrev.00003.2009)
- Guo J, Jou W, Gavrilova O & Hall KD 2009 Persistent diet-induced obesity in male C57BL/6 mice resulting from temporary obesogenic diets. *PLoS ONE* **4** e5370. (doi:10.1371/journal.pone.0005370)
- Gupte AA, Liu JZ, Ren Y, Minze LJ, Wiles JR, Collins AR, Lyon CJ, Pratico D, Finegold MJ, Wong ST, *et al.* 2010 Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. *Hepatology* **52** 2001–2011. (doi:10.1002/hep.23941)
- Hajri T, Han XX, Bonen A & Abumrad NA 2002 Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. *Journal of Clinical Investigation* **109** 1381–1389. (doi:10.1172/JCI0214596)
- Hall AM, Kou K, Chen Z, Pietka TA, Kumar M, Korenblat KM, Lee K, Ahn K, Fabbrini E, Klein S, *et al.* 2012 Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver. *Journal of Lipid Research* **53** 990–999. (doi:10.1194/jlr.P025536)
- Hall AM, Soufi N, Chambers KT, Chen Z, Schweitzer GG, McCommis KS, Erion DM, Graham MJ, Su X & Finck BN 2014 Abrogating monoacylglycerol acyltransferase activity in liver improves glucose tolerance and hepatic insulin signaling in obese mice. *Diabetes* **63** 2284–2296. (doi:10.2337/db13-1502)
- Havel RJ & Hamilton RL 2004 Hepatic catabolism of remnant lipoproteins: where the action is. *Arteriosclerosis Thrombosis and Vascular Biology* **24** 213–215. (doi:10.1161/01.ATV.0000115382.53810.24)
- Hayashi Y, Suemitsu E, Kajimoto K, Sato Y, Akhter A, Sakurai Y, Hatakeyama H, Hyodo M, Kaji N, Baba Y, *et al.* 2014 Hepatic monoacylglycerol O-acyltransferase 1 as a promising therapeutic target for steatosis, obesity, and type 2 diabetes. *Molecular Therapy: Nucleic Acids* **3** e154. (doi:10.1038/mtna.2014.4)
- He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM & Evans RM 2003 Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. *PNAS* **100** 15712–15717. (doi:10.1073/pnas.2536828100)
- Horakova O, Hansikova J, Bardova K, Gardlo A, Rombaldova M, Kuda O, Rossmeisl M & Kopecky J 2016 Plasma acylcarnitines and amino

- acid levels as an early complex biomarker of propensity to high-fat diet-induced obesity in mice. *PLoS ONE* **11** e0155776. (doi:10.1371/journal.pone.0155776)
- Inoue M, Ohtake T, Motomura W, Takahashi N, Hosoki Y, Miyoshi S, Suzuki Y, Saito H, Kohgo Y & Okumura T 2005 Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. *Biochemical and Biophysical Research Communications* **336** 215–222. (doi:10.1016/j.bbrc.2005.08.070)
- Ishibashi S, Herz J, Maeda N, Goldstein JL & Brown MS 1994 The two-receptor model of lipoprotein clearance: tests of the hypothesis in 'knockout' mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. *PNAS* **91** 4431–4435. (doi:10.1073/pnas.91.10.4431)
- Jo H, Choe SS, Shin KC, Jang H, Lee JH, Seong JK, Back SH & Kim JB 2013 Endoplasmic reticulum stress induces hepatic steatosis via increased expression of the hepatic very low-density lipoprotein receptor. *Hepatology* **57** 1366–1377. (doi:10.1002/hep.26126)
- Kineman R, Majumdar N, Subbiah PV & Cordoba-Chacon J 2016 Hepatic PPAR γ is not essential for the rapid development of steatosis following loss of hepatic GH signaling, in adult male mice. *Endocrinology* **157** 1728–1735. (doi:10.1210/en.2015-2077)
- Lade A, Noon LA & Friedman SL 2014 Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. *Current Opinion in Oncology* **26** 100–107. (doi:10.1097/CCO.0000000000000042)
- Lee YJ, Ko EH, Kim JE, Kim E, Lee H, Choi H, Yu JH, Kim HJ, Seong JK, Kim KS, *et al.* 2012 Nuclear receptor PPARgamma-regulated monoacylglycerol O-acyltransferase 1 (MGAT1) expression is responsible for the lipid accumulation in diet-induced hepatic steatosis. *PNAS* **109** 13656–13661. (doi:10.1073/pnas.1203218109)
- Lee JJ, Lambert JE, Hovhannisyan Y, Ramos-Roman MA, Trombold JR, Wagner DA & Parks EJ 2015 Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. *American Journal of Clinical Nutrition* **101** 34–43. (doi:10.3945/ajcn.114.092262)
- Mashek DG 2013 Hepatic fatty acid trafficking: multiple forks in the road. *Advances in Nutrition* **4** 697–710. (doi:10.3945/an.113.004648)
- Matsusue K, Haluzik M, Lambert G, Yim SH, Gavrilova O, Ward JM, Brewer B Jr, Reitman ML & Gonzalez FJ 2003 Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. *Journal of Clinical Investigation* **111** 737–747. (doi:10.1172/JCI200317223)
- Matsusue K, Aibara D, Hayafuchi R, Matsuo K, Takiguchi S, Gonzalez FJ & Yamano S 2014 Hepatic PPARgamma and LXRalpha independently regulate lipid accumulation in the livers of genetically obese mice. *FEBS Letters* **588** 2277–2281. (doi:10.1016/j.febslet.2014.05.012)
- Michelotti GA, Machado MV & Diehl AM 2013 NAFLD, NASH and liver cancer. *Nature Reviews Gastroenterology and Hepatology* **10** 656–665. (doi:10.1038/nrgastro.2013.183)
- Moran-Salvador E, Lopez-Parra M, Garcia-Alonso V, Titos E, Martinez-Clemente M, Gonzalez-Periz A, Lopez-Vicario C, Barak Y, Arroyo V & Claria J 2011 Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. *FASEB Journal* **25** 2538–2550. (doi:10.1096/fj.10-173716)
- Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM & Yu J 2009 Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice. *Scandinavian Journal of Gastroenterology* **44** 358–365. (doi:10.1080/00365520802530861)
- Nassir F, Adewole OL, Brunt EM & Abumrad NA 2013 CD36 deletion reduces VLDL secretion, modulates liver prostaglandins, and exacerbates hepatic steatosis in ob/ob mice. *Journal of Lipid Research* **54** 2988–2997. (doi:10.1194/jlr.M037812)
- Obrowsky S, Chandak PG, Patankar JV, Povoden S, Schlager S, Kershaw EE, Bogner-Strauss JG, Hoefler G, Levak-Frank S & Kratky D 2013 Adipose triglyceride lipase is a TG hydrolase of the small intestine and regulates intestinal PPARalpha signaling. *Journal of Lipid Research* **54** 425–435. (doi:10.1194/jlr.M031716)
- Pettinelli P & Videla LA 2011 Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. *Journal of Clinical Endocrinology and Metabolism* **96** 1424–1430. (doi:10.1210/jc.2010-2129)
- Rahimian R, Masih-Khan E, Lo M, van Breemen C, McManus BM & Dube GP 2001 Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus. *Molecular and Cellular Biochemistry* **224** 29–37. (doi:10.1023/A:1011927113563)
- Ratz V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, Podevin P, Lacorte JM, Bernhardt C, Bruckert E, *et al.* 2008 Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. *Gastroenterology* **135** 100–110. (doi:10.1053/j.gastro.2008.03.078)
- Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, *et al.* 2010 Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. *New England Journal of Medicine* **362** 1675–1685. (doi:10.1056/NEJMoa0907929)
- Schadlinger SE, Bucher NL, Schreiber BM & Farmer SR 2005 PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. *American Journal of Physiology: Endocrinology and Metabolism* **288** E1195–E1205. (doi:10.1152/ajpendo.00513.2004)
- Sevastianova K, Santos A, Kotronen A, Hakkarainen A, Makkonen J, Silander K, Peltonen M, Romeo S, Lundbom J, Lundbom N, *et al.* 2012 Effect of short-term carbohydrate overfeeding and long-term weight loss on liver fat in overweight humans. *American Journal of Clinical Nutrition* **96** 727–734. (doi:10.3945/ajcn.112.038695)
- Shin S, Wangenstein KJ, Teta-Bissett M, Wang YJ, Mosleh-Shirazi E, Buza EL, Greenbaum LE & Kaestner KH 2016 Genetic lineage tracing analysis of the cell of origin of hepatotoxin-induced liver tumors in mice. *Hepatology* **64** 1163–1177. (doi:10.1002/hep.28602)
- Silbernagel G, Kovarova M, Cegan A, Machann J, Schick F, Lehmann R, Haring HU, Stefan N, Schleicher E, Fritsche A, *et al.* 2012 High hepatic SCD1 activity is associated with low liver fat content in healthy subjects under a lipogenic diet. *Journal of Clinical Endocrinology and Metabolism* **97** E2288–E2292. (doi:10.1210/jc.2012-2152)
- Soufi N, Hall AM, Chen Z, Yoshino J, Collier SL, Mathews JC, Brunt EM, Albert CJ, Graham MJ, Ford DA, *et al.* 2014 Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice. *Journal of Biological Chemistry* **289** 30177–30188. (doi:10.1074/jbc.M114.595850)
- Steneberg P, Sykaras AG, Backlund F, Straseviciene J, Soderstrom I & Edlund H 2015 Hyperinsulinemia enhances hepatic expression of the fatty acid transporter Cd36 and provokes hepatosteatosis and hepatic insulin resistance. *Journal of Biological Chemistry* **290** 19034–19043. (doi:10.1074/jbc.M115.640292)
- Tao H, Aakula S, Abumrad NN & Hajri T 2010 Peroxisome proliferator-activated receptor-gamma regulates the expression and function of very-low-density lipoprotein receptor. *American Journal of Physiology: Endocrinology and Metabolism* **298** E68–E79. (doi:10.1152/ajpendo.00367.2009)
- Tontonoz P, Nagy L, Alvarez JG, Thomazy VA & Evans RM 1998 PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. *Cell* **93** 241–252. (doi:10.1016/S0092-8674(00)81575-5)
- Wilson CG, Tran JL, Erion DM, Vera NB, Febbraio M & Weiss EJ 2015 Hepatocyte-specific disruption of CD36 attenuates fatty liver and improves insulin sensitivity in HFD fed mice. *Endocrinology* **157** 570–585. (doi:10.1210/en.2015-1866)

- Xu A, Wang Y, Keshaw H, Xu LY, Lam KS & Cooper GJ 2003 The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. *Journal of Clinical Investigation* **112** 91–100. (doi:10.1172/JCI200317797)
- Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, *et al.* 2002 Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. *Nature Medicine* **8** 1288–1295. (doi:10.1038/nm788)
- Yamazaki T, Shiraishi S, Kishimoto K, Miura S & Ezaki O 2011 An increase in liver PPARgamma2 is an initial event to induce fatty liver in response to a diet high in butter: PPARgamma2 knockdown improves fatty liver induced by high-saturated fat. *Journal of Nutritional Biochemistry* **22** 543–553. (doi:10.1016/j.jnutbio.2010.04.009)
- Yang P & Subbaiah PV 2015 Regulation of hepatic lipase activity by sphingomyelin in plasma lipoproteins. *Biochimica et Biophysica Acta* **1851** 1327–1336. (doi:10.1016/j.bbali.2015.07.003)
- Yanger K, Knigin D, Zong Y, Maggs L, Gu G, Akiyama H, Pikarsky E & Stanger BZ 2014 Adult hepatocytes are generated by self-duplication rather than stem cell differentiation. *Cell Stem Cell* **15** 340–349. (doi:10.1016/j.stem.2014.06.003)
- Yen CL, Stone SJ, Cases S, Zhou P & Farese RV Jr 2002 Identification of a gene encoding MGAT1, a monoacylglycerol acyltransferase. *PNAS* **99** 8512–8517. (doi:10.1073/pnas.132274899)
- Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H & Srishord M 2011 Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. *Clinical Gastroenterology and Hepatology* **9** 524–530.e521; quiz e560. (doi:10.1016/j.cgh.2011.03.020)
- Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, Rao MS, Gonzalez FJ & Reddy JK 2003 Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. *Journal of Biological Chemistry* **278** 498–505. (doi:10.1074/jbc.M210062200)
- Yu JH, Lee YJ, Kim HJ, Choi H, Choi Y, Seok JW & Kim JW 2015 Monoacylglycerol O-acyltransferase 1 is regulated by peroxisome proliferator-activated receptor gamma in human hepatocytes and increases lipid accumulation. *Biochemical and Biophysical Research Communications* **460** 715–720. (doi:10.1016/j.bbrc.2015.03.095)
- Yu JH, Song SJ, Kim A, Choi Y, Seok JW, Kim HJ, Lee YJ, Lee KS & Kim JW 2016 Suppression of PPARgamma-mediated monoacylglycerol O-acyltransferase 1 expression ameliorates alcoholic hepatic steatosis. *Scientific Reports* **6** 29352. (doi:10.1038/srep29352)
- Zezos P & Renner EL 2014 Liver transplantation and non-alcoholic fatty liver disease. *World Journal of Gastroenterology* **20** 15532–15538. (doi:10.3748/wjg.v20.i42.15532)
- Zhang YL, Hernandez-Ono A, Siri P, Weisberg S, Conlon D, Graham MJ, Crooke RM, Huang LS & Ginsberg HN 2006 Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. *Journal of Biological Chemistry* **281** 37603–37615. (doi:10.1074/jbc.M604709200)
- Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, Lee JH, Khadem S, Ren S, Li S, *et al.* 2008 Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. *Gastroenterology* **134** 556–567. (doi:10.1053/j.gastro.2007.11.037)

Received in final form 5 October 2016

Accepted 25 October 2016

Accepted Preprint published online 31 October 2016